Real-world Experiences in the Transplantation of Hepatitis C-NAAT–positive Organs

作者
Julie M. Steinbrink,Jennifer S. Byrns,Carl Lansing Berg,Matthew Robert Kappus,Lindsay Y. King,Matthew J. Ellis,Scott Sanoff,Richa Agarwal,Adam D. DeVore,John Michael Reynolds,Matthew Galen Hartwig,Carmelo A. Milano,Debra Lynn Sudan,Eileen K Maziarz,Jennifer L. Saullo,Barbara Dudley Alexander,Cameron R. Wolfe
出处
期刊:Transplantation direct [Wolters Kluwer]
卷期号:9 (11): e1539-e1539 被引量:5
标识
DOI:10.1097/txd.0000000000001539
摘要

Background: Hepatitis C virus (HCV) nucleic acid amplification test (NAAT)-positive donors have increased the organ pool. Direct-acting antivirals (DAAs) have led to high rates of treatment success and sustained virologic response (SVR) in recipients with donor-derived HCV infection without significant adverse effects, although variability remains in the timing and duration of antivirals. Methods: This retrospective study analyzed all adult HCV-NAAT-negative transplant recipients who received an organ from HCV-NAAT-positive donors from November 24, 2018, to March 31, 2022, at Duke University Medical Center with protocolized delay of DAA initiation until after hospital discharge, with at least 180-d follow-up on all patients. Transplant and HCV-related outcomes were analyzed. Results: Two hundred eleven transplants (111 kidneys, 41 livers, 34 hearts, and 25 lungs) were performed from HCV-NAAT-positive donors to HCV-NAAT-negative recipients. Ninety percent of recipients became viremic within 7 d posttransplant. Ninety-nine percent of recipients were initiated on pangenotypic DAAs in the outpatient setting a median of 52 d posttransplant, most commonly with 12-wk courses of sofosbuvir-velpatasvir (lungs) and glecaprevir-pibrentasvir (heart, kidney, and liver). Ninety-seven percent of recipients had SVR after a first-line DAA; all ultimately achieved SVR at 12 wk after subsequent treatment courses. The median peak HCV RNA for all organ systems was 2 436 512 IU/mL; the median time from antiviral to undetectable RNA was 48 d, although differences were noted between organ groups. No patient deaths or graft losses were directly attributable to HCV infection. Conclusions: One hundred percent of transplant recipients of HCV-NAAT-positive organs ultimately developed SVR without significant adverse effects when HCV antivirals were initiated in the outpatient setting after transplant hospitalization, suggesting that this real-world treatment pathway is a viable option.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
鱼鱼完成签到,获得积分10
刚刚
刚刚
在水一方的应助被675675采纳,获得10
2秒前
幸福台灯完成签到,获得积分10
2秒前
Captainhana完成签到,获得积分10
4秒前
5秒前
嘤嘤嘤发布了新的文献求助10
6秒前
三千白发生完成签到,获得积分10
6秒前
纳古菌完成签到,获得积分10
7秒前
SG完成签到,获得积分10
7秒前
听话的无极完成签到,获得积分10
7秒前
7秒前
123456完成签到,获得积分10
8秒前
努力小人完成签到,获得积分10
8秒前
9秒前
liang完成签到,获得积分10
9秒前
9秒前
青葙完成签到,获得积分10
10秒前
123456发布了新的文献求助10
11秒前
11NING发布了新的文献求助10
12秒前
Ysk完成签到,获得积分10
12秒前
14秒前
675675发布了新的文献求助10
16秒前
汉堡包的应助被小艾同学采纳,获得10
16秒前
17秒前
20秒前
11NING完成签到,获得积分10
20秒前
20秒前
SCI完成签到,获得积分10
21秒前
Koi发布了新的文献求助10
21秒前
禹hs完成签到,获得积分10
24秒前
吱ing完成签到 ,获得积分10
25秒前
ding的应助被bbb采纳,获得10
25秒前
SCI发布了新的文献求助10
25秒前
ZeSheng完成签到,获得积分10
26秒前
27秒前
27秒前
27秒前
眠龙完成签到 ,获得积分10
28秒前
猪猪侠完成签到,获得积分10
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568